StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $5.43 | $5.41 | -0.37% | 0.4M |
| 05-12 | $5.42 | $5.50 | +1.48% | 0.3M |
| 05-13 | $5.25 | $4.57 | -12.95% | 1.0M |
| 05-14 | $4.57 | $4.27 | -6.56% | 0.7M |
| 05-15 | $4.22 | $4.10 | -2.84% | 0.5M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for AVIR.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Fundamentals not available for AVIR.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
| Metric | Annual 2021 2021-12-31 | Q3 2021 2021-09-30 | Q2 2021 2021-06-30 | Q1 2021 2021-03-31 |
|---|---|---|---|---|
Revenue | $351.37M | $159.19M | $126.38M | $65.98M |
Operating Income | $138.38M | $17.20M | $39.34M | $30.66M |
Net Income | $121.19M | $4.06M | $1.54M | $30.71M |
EPS (Diluted) | $1.37 | $0.05 | $0.36 | $0.34 |
Total Assets | $772.89M | $843.50M | $871.54M | $840.65M |
Total Liabilities | $62.81M | $262.05M | $273.68M | $254.39M |
Cash & Equivalents | $764.38M | $839.66M | $816.46M | $833.75M |
Free Cash Flow OCF − CapEx | $-87.01M | Not available | Not available | Not available |
Shares Outstanding | 83.10M | 83.05M | 82.78M | 82.74M |